Liraglutide decreases postprandial fibroblast growth factor 19 and glucagon-like peptide 2, and increases postprandial cholecystokinin in individuals with obesity

Research output: Contribution to journalConference abstract in journal

Original languageEnglish
Article number177
JournalDiabetologia
Volume64
Issue numberSUPPL 1
Pages (from-to)94-94
ISSN0012-186X
DOIs
Publication statusPublished - 2021

ID: 286506992